In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 Drug Master File in Korea (BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1. The MFDS reviews the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF as part of the drug registration process and uses the information provided in the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with KDMF on PharmaCompass.